Rifampicin for non-tuberculous infections?

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Rifampicin (RIF) is a key antibiotic for tuberculosis treatment.
• Concerns exist regarding RIF use in short courses for non-tuberculous infections due to potential resistance.
• Understanding RIF's efficacy and resistance-inducing potential under varied concentrations is crucial.

Purpose of the Study:

• To investigate the efficacy of cyclically changing rifampicin concentrations against Mycobacterium tuberculosis in vitro.
• To determine if such exposure regimens can prevent the emergence of rifampicin resistance.
• To inform the debate on using rifampicin for short-course treatment of non-tuberculous infections.

Main Methods:

• Exposing large populations of rifampicin-sensitive Mycobacterium tuberculosis strains to fluctuating rifampicin concentrations in vitro.
• Simulating blood level changes observed during actual drug treatment.
• Conducting experiments with 7-day and 14-day cyclic rifampicin exposure periods.

Main Results:

• Complete elimination of Mycobacterium tuberculosis test strains was achieved.
• No emergence of rifampicin resistance was observed during the experimental periods.
• The study demonstrated successful eradication without compromising drug susceptibility.

Conclusions:

• Cyclic rifampicin exposure, mimicking therapeutic blood level fluctuations, can effectively eliminate M. tuberculosis without inducing resistance.
• The findings challenge the rationale for withholding rifampicin from short-course treatments for non-tuberculous infections.
• Evidence supporting the restriction of rifampicin use in such scenarios appears limited, warranting a re-evaluation.